Skip to main content

Table 3 Rates of clinical tumor regression in studies of adoptive transfer of tumor-reactive lymphocytes

From: Progress and controversies in developing cancer vaccines

Type of therapy

Initial rate of objective responses

Subsequent rate of objective responses

Conclusion

LAK cell therapy + high-dose (HD) IL2

44% (11/25) [ref 34]

22% (23/106) [ref 35]

Response rate not better than HD IL2 alone (28 vs 22%), but trend toward improved survival with LAK+IL2 for melanoma (p = 0.064) [refs 36,37]

TIL therapy + HD IL2

55% (11/20) [ref 38]

22% (9/41) [ref 39]

Not better than HD IL2 alone [ref 39]. Median duration of partial responses 4 months [ref 40].

Selected TIL therapy after lymphoablation + HD IL2

51% (18/35) [ref 33]

Pending

Results preliminary